A stage IV high-grade serous ovarian cancer patient carrying ERBB2 amplification and ERBB2 overexpression benefits from late-line pyrotinib treatment: A case report
Open Access
- 22 July 2025
- journal article
- case report
- Published by SAGE Publications in Science Progress
- Vol. 108 (3)
Abstract
Ovarian cancer (OC), one of the most common gynecological cancers, is usually diagnosed at an advanced stage. High-grade serous ovarian cancer (HGSOC) is a histological subtype of OC that accounts for approximately 70% of all OC cases. erb-b2 receptor tyrosine kinase 2 (ERBB2) overexpression commonly occurs in HGSOC, accounting for 12.5% of stage III and IV HGSOCs. Currently, there is no established treatment strategy for OC patients with ERBB2 amplification or ERBB2 overexpression. Whether these patients will benefit from ERBB2 inhibitors remains unclear. Herein, we report a patient with metastatic HGSOC carrying ERBB2 amplification and ERBB2 overexpression. Following progression to platinum-based chemotherapy and subsequent antiangiogenic therapies, the patient benefited from late-line pyrotinib treatment, achieving stable disease with a progression-free survival of 9.5 months. Our study provides preliminary clinical evidence supporting pyrotinib as a feasible treatment option for metastatic HGSOC patients with ERBB2 amplification and/or ERBB2 overexpression. Prospective trials of pyrotinib should be conducted in appropriately selected OC populations.Keywords
Funding Information
- the national key Research and Development Program of China (2020YFC0122302)
This publication has 42 references indexed in Scilit:
- MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian CancerClinical Cancer Research, 2016
- Cancer statistics in China, 2015CA: A Cancer Journal for Clinicians, 2016
- Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trialThe Lancet Oncology, 2015
- New Strategies in Ovarian Cancer: Translating the Molecular Complexity of Ovarian Cancer into Treatment AdvancesClinical Cancer Research, 2014
- The CARE Guidelines: Consensus‐Based Clinical Case Reporting Guideline DevelopmentHeadache: The Journal of Head and Face Pain, 2013
- Metastatic Mucinous Ovarian Cancer and Treatment Decisions Based on Histology and Molecular Markers Rather Than the Primary LocationJournal of the National Comprehensive Cancer Network, 2012
- HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapyBMC Cancer, 2009
- Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation StatusJournal of Clinical Oncology, 2006
- Ovarian TumorigenesisThe American Journal of Pathology, 2004
- Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology GroupJournal of Clinical Oncology, 2003